Faculty introduction, disclosures

HFrEF introductory content  Epidemiology  Pathophysiology: structural and functional changes  Burden of HFrEF on patients and the healthcare system

Treatment of HFrEF  Present pharmacotherapy, clinical trial findings, and guideline updates, with a focus on outpatient management of chronic HF  Initial therapy  RASis  Beta blockers  MRBs  SGLT2is  Ongoing symptoms and the roles of:  Hydralazine with isosorbide dinitrate  Soluble guanylate cyclase stimulation  If channel inhibition  Digoxin  Investigational therapy: cardiac myosin activation  Practical considerations in therapeutic optimization  Management of associated condition (e.g., valvular disease, ischemic heart disease, arrhythmias)  Importance of initiating therapy soon after diagnosis: focus on outcomes  Medication adverse effects: which ones should alter the course of treatment, and when?  Medication adherence and barriers to attaining target dose  Difficult cases: treatment-refractory outpatients  Facilitating referral to a specialist  Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Summarize the health burden unique to patients with heart failure (HF) and challenges to optimal management.
• Recall the present and emerging therapies for HF with reduced ejection fraction (HFrEF) and their current or anticipated roles in the treatment paradigm.
• Develop a treatment plan for a patient with HF.

ACCME Activity #202792417

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Matt Budoff, MD, FACC, Professor of Medicine, David Geffen School of Medicine at UCLA, has received financial compensation from Merck, Astra Zeneca and Boehringer Ingleheim for speaker's bureau work; in addition to grant/research support for Merck.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL NOT discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck. 

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version